Amivantamab (JNJ-61186372) 是一种人源 EGFR-MET 双特异性抗体，具有免疫抗癌活性。Amivantamab 可以抑制配体结合，促进受体-抗体复合物的内吞作用和降解，并诱导巨噬细胞的 Fc 依赖性胞吞作用和自然杀伤细胞的抗体依赖性细胞毒性。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

Anti-cMet & EGFR Reference Antibody (Amivantamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-cMet & EGFR Reference Antibody (Amivantamab) is 98.79%, determined by SEC-HPLC.

Amivantamab bound to ERBB1/EGFR/HER1 protein, and then rebounded to secondary antibodies(Anti-Human-κ+λ-HRP) , and read OD450. As shown in fig, Amivantamab bound human ERBB1/EGFR/HER1 Protein-Fc, and the EC50 was 0.232 nM.

Amivantamab bound to cMet protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Amivantamab bound human cMet Protein-His, and the EC50 was 0.004 nM.

Amivantamab bound to EGFR-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Amivantamab bound to EGFR-CHO-K cells, and the EC50 was 2.161 nM.

Amivantamab bound to huMet-HEK293(A3) cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Amivantamab bound to huMet-HEK293(A3) cells, and the EC50 was 0.609 nM.

Co-incubation of Amivantamab with HGF, then with the addition of Human c-MET (Luc) HEK293 Reporter cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Amivantamab was able to block HGF/c-Met signaling pathway, and the IC50 was 0.166 nM.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.